Relapsing/refractory ALK+ anaplastic large cell lymphoma

Clinical trials for Relapsing/refractory ALK+ anaplastic large cell lymphoma explained in plain language.

Never miss a new study

Get alerted when new Relapsing/refractory ALK+ anaplastic large cell lymphoma trials appear

Sign up with your email to follow new studies for Relapsing/refractory ALK+ anaplastic large cell lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Immunotherapy drug nivolumab takes on rare blood cancer in kids and adults

Disease control Ongoing

This study tests the immunotherapy drug nivolumab in 45 children and adults with a rare blood cancer called ALK-positive anaplastic large cell lymphoma that has come back or not responded to treatment. Participants are split into two groups: those with active disease to see if th…

Matched conditions: RELAPSING/REFRACTORY ALK+ ANAPLASTIC LARGE CELL LYMPHOMA

Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control

Last updated Jun 27, 2026 12:04 UTC

Relapsing/refractory ALK+ anaplastic large cell lymphoma

Get alerted when new Relapsing/refractory ALK+ anaplastic large cell lymphoma trials appear

Immunotherapy drug nivolumab takes on rare blood cancer in kids and adults